Stock AnalizZenas BioPharma, Inc. ZBIO
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Zenas BioPharma, Inc. (ZBIO) is a healthcare company listed in the US with a market value of about $1.9B. In the twelve months to September 30, 2026 it had revenue of $11M and net income of -$542M, a net margin of -4925.5%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -80%.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $11M | $10M | $5M | $50M |
| Net income | -$542M | -$378M | -$157M | -$37M |
| Free cash flow | -$243M | -$172M | -$120M | -$31M |
| EPS (diluted) | $-10.05 | $-8.44 | $-11.89 | $-24.25 |
| Net margin | -4925.5% | -3777.4% | -3139.8% | -74.2% |
| ROIC | — | -118.9% | -41.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $47.88, 71% above the current price; targets range from $32.00 to $59.00; the consensus rating is “Strong buy”; expected EPS is $-5.62 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Zenas BioPharma pay a dividend?
Not currently.
Is Zenas BioPharma a good stock to buy?
We do not give buy or sell advice. Zenas BioPharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.